14 results on '"Hudis, Clifford A."'
Search Results
2. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
- Author
-
Baselga, José, Costa, Frederico, Gomez, Henry, Hudis, Clifford A., Rapoport, Bernardo, Roche, Henri, Schwartzberg, Lee S., Shan, Minghua, Petrenciuc, Oana, and Gradishar, William J.
- Subjects
PLACEBOS ,CANCER treatment ,METASTASIS ,HER2 protein ,BREAST cancer treatment ,RANDOMIZED controlled trials ,KINASE inhibitors ,ADVERSE health care events ,HAND-foot syndrome - Abstract
Background: Sorafenib is an oral multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized phase 2b screening trial in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer demonstrated a significant improvement in progression-free survival (PFS) when sorafenib was added to capecitabine versus placebo (median 6.4 versus 4.1 months; hazard ratio = 0.58; P = 0.001). Most drug-related adverse events were Grade 1/2 in severity with the exception of Grade 3 hand-foot skin reaction/syndrome (44% versus 14%, respectively). These results suggest a role for the combination of sorafenib and capecitabine in breast cancer and supported a phase 3 confirmatory trial. Here we describe RESILIENCE - a multinational, double-blind, randomized, placebo-controlled, phase 3 trial - assessing the addition of sorafenib to first- or second-line capecitabine in advanced HER2-negative breast cancer. Methods/design: Eligibility criteria include ⩾18 years of age, ⩽1 prior chemotherapy regimen for metastatic disease, and resistant to/failed taxane and anthracycline or no indication for further anthracycline. Prior treatment with a vascular endothelial growth factor inhibitor is not allowed. Patients with significant cardiovascular disease or active brain metastases are not eligible. Patients are stratified by hormone-receptor status, geographic region, and prior metastatic chemotherapy status and randomized (1:1) to capecitabine (1000 mg/m2 orally twice daily (BID), days 1 to 14 of 21) in combination with sorafenib (orally BID, days 1 to 21, total dose 600 mg/day) or matching placebo. Capecitabine and sorafenib/placebo doses can be escalated to 1250 mg/m2 BID and 400 mg BID, respectively, as tolerated, or reduced to manage toxicity. Dose re-escalation after a reduction is allowed for sorafenib/placebo but not for capecitabine. This dosing algorithm was designed to mitigate dermatologic and other toxicity, in addition to detailed guidelines for prophylactic and symptomatic treatment. Radiographic assessment is every 6 weeks for 36 weeks, and every 9 weeks thereafter. The primary endpoint is PFS by blinded independent central review (Response Evaluation Criteria in Solid Tumors 1.1 criteria). Secondary endpoints include overall survival, time to progression, overall response rate, duration of response, and safety. Enrollment began in November 2010 with a target of approximately 519 patients Discussion: RESILIENCE will provide definitive PFS data for the combination of sorafenib and capecitabine in advanced HER2-negative breast cancer and better characterize the benefit-to-risk profile. Trial registration: Clinicaltrials.gov, NCT01234337 [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
3. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
- Author
-
Kiess, Ana P., McArthur, Heather L., Mahoney, Kathleen, Patil, Sujata, Morris, Patrick G., Ho, Alice, Hudis, Clifford A., and McCormick, Beryl
- Subjects
ADJUVANT treatment of cancer ,THERAPEUTIC use of monoclonal antibodies ,EPIDERMAL growth factor receptors ,TRASTUZUMAB ,CANCER in women ,ANTINEOPLASTIC agents ,CANCER treatment ,THERAPEUTICS - Abstract
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer have a higher risk of locoregional recurrence (LRR), even in the setting of early stage, lymph node-negative disease. In this sequential, retrospective study, the authors evaluated whether adjuvant trastuzumab was associated with reduced LRR in women with lymph node-negative, HER2-positive disease who received breast-conservation therapy (BCT). METHODS: By using an institutional database, 197 women were identified who had lymph node-negative, HER2-positive breast cancer measuring ≤5 cm diagnosed between 2002 and 2008 and who received BCT, including whole-breast irradiation. Two cohorts were compared: 70 women who did not receive trastuzumab (the no-trastuzumab cohort) and 102 women who did receive trastuzumab (the trastuzumab cohort). Kaplan-Meier methods were used to estimate LRR-free survival. RESULTS: The 2 cohorts were similar in age, tumor size, histology, and hormone receptor status. Chemotherapy was received by 73% of the no-trastuzumab cohort and by 100% of the trastuzumab cohort. In both groups, 99% of patients completed radiotherapy with a median dose of 60 Gray. The median recurrence-free follow-up was 86 months for the no-trastuzumab cohort and 47 months for the trastuzumab cohort. The 3-year LRR-free survival rate was 90% (95% confidence interval, 83%-97%) for the no-trastuzumab cohort and 99% (95% confidence interval, 97%-100%) for the trastuzumab cohort. In the no-trastuzumab cohort, LRR occurred in 7 patients (median time to LRR, 14 months). In the trastuzumab cohort, there was 1 LRR at 14 months. CONCLUSIONS: Even among women with lower risk breast cancer, the relatively high locoregional failure rates associated with positive HER2 status could be reduced markedly with adjuvant trastuzumab chemotherapy. Within 3 years, a 10% LRR rate without trastuzumab and a 1% LRR rate with trastuzumab were observed in women with lymph node-negative disease who received BCT. Cancer 2012. © 2011 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
4. Updates in adjuvant systemic treatment of breast cancer.
- Author
-
McArthur, Heather L. and Hudis, Clifford A.
- Subjects
BREAST cancer ,CANCER treatment ,CANCER in women ,DRUG therapy - Abstract
Abstract: Breast cancer is a significant public health burden with more than 200,000 new cases diagnosed in the United States each year. Although many incident cases represent localized disease, a significant proportion of women with early stage breast cancer eventually experience a distant relapse and ultimately die of metastatic breast cancer complications. Consequently, investigators strive to improve the adjuvant treatment paradigm and thus, optimize outcomes for women with early stage breast cancer. Within the last year a study describing a decline in incident breast cancer cases in the United States was reported. In addition, the results from a number of notable adjuvant treatment studies were reported or updated. Innovations in taxane-containing strategies and dose dense chemotherapy strategies were prominently featured. In addition, a number of insights pertaining to the treatment of women with HER2-positive breast cancer were reported. An overview of selected recently reported studies will be reviewed here. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
5. Has first-line therapy had an impact on general outcome in metastatic breast cancer?
- Author
-
McArthur, Heather L. and Hudis, Clifford A.
- Subjects
BREAST cancer treatment ,CANCER treatment ,DISEASES in women ,METASTASIS ,DRUGS ,PUBLIC health - Abstract
According to the WHO World Cancer Report, 2003, breast cancer is a global public health burden with more than one million new cases diagnosed worldwide each year. Despite the diminished frequency of advanced-stage disease at initial diagnosis in some parts of the world, a significant proportion of women with early-stage disease eventually experience distant recurrences. Metastatic breast cancer is generally incurable and treatment is aimed at extending survival and improving quality-of-life. Efforts to optimize these paradigms are ongoing. In the last 30 years, significant innovations in drug delivery, scheduling and biologic therapies have resulted in significant improvements in disease-specific outcomes in the metastatic setting. One hopes that ongoing innovations, particularly in targeted therapy, will continue to translate into further improvements in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
6. Breast Cancer Chemotherapy.
- Author
-
McArthur, Heather L. and Hudis, Clifford A.
- Subjects
BREAST cancer ,DRUG therapy ,CANCER treatment ,CANCER relapse ,IMMUNOTHERAPY - Abstract
The article provides information on breast cancer chemotherapy. According to the article, adjuvant chemotherapy recommendations are generally made by estimating an individual's risk of recurrence and the expected benefit of therapy. Modern adjuvant strategies comprises one or more chemotherapy agents, hormonal maneuvers, immunotherapy agents, or experimental agents.
- Published
- 2007
- Full Text
- View/download PDF
7. Current status of the taxanes as adjuvant therapy for breast cancer.
- Author
-
Hudis, Clifford, McArthur, Heather, and Dang, Chau
- Subjects
ADJUVANT treatment of cancer ,CANCER treatment ,BREAST cancer ,CANCER patients ,CLINICAL trials - Abstract
Abstract: Adjuvant chemotherapy for breast cancer reduces the risks of recurrence and death in many subsets of patients. The quest for better regimens, defined as both more effective and less toxic has led to numerous clinical trials testing the taxanes in the adjuvant setting. These trials are generally positive but do not clearly identify a single best or ideal regimen for all patients. This paper reviews the available data in this area of clinical research. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
8. The best use of adjuvant chemotherapy: New drugs and new use of “old” drugs.
- Author
-
Hudis, Clifford
- Subjects
ADJUVANT treatment of cancer ,BREAST cancer ,CANCER chemotherapy ,ANTHRACYCLINES ,CANCER treatment ,CLINICAL trials - Abstract
Summary: Modern chemotherapy has diminished the risks of distant relapse and death in many subgroups of patients with early stage breast cancer. Although the initial trials relied on empirically designed regimens, studies are increasingly based on preclinical science and reflect the growing understanding of the molecular basis of cancer. Empiric clinical trials proved the worth of combination chemotherapy, the limited value of very long courses of treatment, and the benefits of adding first anthracyclines and then later taxanes. More recent trials have demonstrated the limits on empiric dose escalation and the benefits of optimized scheduling. Many trials are currently focused on novel targeted agents. Based on several decades of studies in thousands of women it is reasonable to consider a combination of chemotherapy agents for patients with hormone unresponsive or otherwise high-risk tumors. Anthracyclines and taxanes should be incorporated into the treatment plans of patients in the higher risk subsets and the specific regimens should be taken from the several randomized studies. When available, eligible patients should be enrolled on prospective clinical trials. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
9. Effect of Creatinine Clearance on Patterns of Toxicity in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer.
- Author
-
Hurria, Arti, Hurria, Anju, Brogan, Kelly, Panageas, Katherine S., Pearce, Carol, Norton, Larry, Jakubowski, Ann, Howard, Jane, and Hudis, Clifford
- Subjects
CANCER treatment ,DRUG therapy ,BREAST cancer ,CANCER chemotherapy ,CREATININE - Abstract
Objective: A number of age-related physiological changes contribute to an increased risk of toxicity of cancer chemotherapy in the elderly. One of the most important of these changes is the progressive decline in renal function with aging. We sought to determine the association between calculated creatinine clearance (CLCR) and grade 3 or 4 toxicities during adjuvant chemotherapy in women ≥65 years of age with breast cancer. Design and methods: We identified 1405 patients ≥65 years of age who had been treated for primary invasive breast cancer at Memorial Sloan-Kettering Cancer Center between January 1998 and December 2000. Patients were included in this analysis if they had stage I-III breast cancer and had received adjuvant chemotherapy. Patients were excluded if they had a prior history of breast cancer or chemotherapy, or had no baseline creatinine value available for review. Results: The 126 patients who met our criteria had received either cyclophosphamide, methotrexate and fluorouracil (CMF) [n = 65, mean age 71, range 65-78] or an anthracycline-based regimen (n = 61, mean age 69, range 65-79). The majority of patients (97%) had a normal creatinine. CLCR, as calculated by the Cockcroft-Gault and Jeliffe formulas, decreased with increasing age (increased age associated with decreased Cockcroft-Gault [p = 0.02]; increased age associated with decreased Jeliffe [p < 0.01]). In multivariate analysis, after controlling for age and co-morbidity, a CLCR <50 mL/min by the Cockcroft-Gault formula was associated with an increased risk of fever and neutropenia (odds ratio [OR] 3.60; 95% CI 1.00, 12.94; p = 0.05) and a CLCR <50 mL/min by the Jeliffe formula was associated with a trend towards an increased risk of fever and neutropenia (OR 3.30; 95% CI 0.91, 12.33; p = 0.07), grade 3 or 4 haematological toxicity (OR 2.43; 95% CI 0.90, 6.55; p = 0.08), and need for erythropoietin (OR 4.15; 95% CI 0.81, 2.99; p = 0.09). An increase in creatinine (as a continuous variable) was associated with a trend towards an increased risk of grade 3 or 4 haematological toxicity (OR 5.81; 95% CI 0.96, 35.33; p = 0.06). Conclusions: In this cohort of older breast cancer patients, a decreased CLCR and increased creatinine was associated with an increased risk of fever and neutropenia or haematological toxicity. CL
CR should be considered when determining chemotherapy dosage in the elderly. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
10. Adjuvant Therapy For Breast Cancer: Practical Lessons From The Early Breast Cancer Trialists' Collaborative Group.
- Author
-
Hudis, Clifford A. and Dang, Chau T.
- Subjects
- *
BREAST cancer , *CANCER treatment , *IMMUNOLOGICAL adjuvants , *CLINICAL trials , *CLINICAL medicine , *IMMUNOMODULATORS - Abstract
This article focuses on adjuvant breast cancer therapy. Increased early detection and improved treatment have made clinical cure possible for more patients with breast cancer than ever before. The medical oncologist contributes to this outcome through participation in the multidisciplinary care of patients with early stage disease and by providing systemic adjuvant therapy designed to treat undetectable metastatic foci of disease. The article reviews the metaanalyses performed every fifth year at Oxford University to provide a foundation for clinical practice, and clinical trials.
- Published
- 2004
- Full Text
- View/download PDF
11. Big data: Are large prospective randomized trials obsolete in the future?
- Author
-
Hudis, Clifford A.
- Subjects
CANCER treatment ,RANDOMIZED controlled trials ,DATA analysis ,BIG data ,EVIDENCE-based medicine - Abstract
Big data represents a new opportunity to increase our understanding of cancer care as it is practiced globally and to improve it through the refinement of clinic guidelines and the identification of knowledge gaps. Here we review the historical approach to evidence development (randomized clinical trials), some of their limitations, and the complementary role that big data analytics may play. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Mastectomy With Immediate Expander-Implant Reconstruction, Adjuvant Chemotherapy, and Radiation for Stage II–III Breast Cancer: Treatment Intervals and Clinical Outcomes
- Author
-
Wright, Jean L., Cordeiro, Peter G., Ben-Porat, Leah, Van Zee, Kimberly J., Hudis, Clifford, Beal, Kathryn, and McCormick, Beryl
- Subjects
- *
CANCER treatment , *THERAPEUTICS , *DRUGS , *PHARMACOLOGY - Abstract
Purpose: To determine intervals between surgery and adjuvant chemotherapy and radiation in patients treated with mastectomy with immediate expander-implant reconstruction, and to evaluate locoregional and distant control and overall survival in these patients. Methods and Materials: Between May 1996 and March 2004, 104 patients with Stage II–III breast cancer were routinely treated at our institution under the following algorithm: (1) definitive mastectomy with axillary lymph node dissection and immediate tissue expander placement, (2) tissue expansion during chemotherapy, (3) exchange of tissue expander for permanent implant, (4) radiation. Patient, disease, and treatment characteristics and clinical outcomes were retrospectively evaluated. Results: Median age was 45 years. Twenty-six percent of patients were Stage II and 74% Stage III. All received adjuvant chemotherapy. Estrogen receptor staining was positive in 77%, and 78% received hormone therapy. Radiation was delivered to the chest wall with daily 0.5-cm bolus and to the supraclavicular fossa. Median dose was 5040 cGy. Median interval from surgery to chemotherapy was 5 weeks, from completion of chemotherapy to exchange 4 weeks, and from exchange to radiation 4 weeks. Median interval from completion of chemotherapy to start of radiation was 8 weeks. Median follow-up was 64 months from date of mastectomy. The 5-year rate for locoregional disease control was 100%, for distant metastasis-free survival 90%, and for overall survival 96%. Conclusions: Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation results in a median interval of 8 weeks from completion of chemotherapy to initiation of radiation and seems to be associated with acceptable 5-year locoregional control, distant metastasis-free survival, and overall survival. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
13. HER2 and Response to Paclitaxel in Node-Positive Breast Cancer.
- Author
-
Hayes, Daniel F., Thor, Ann D., Dressler, Lynn G., Weaver, Donald, Edgerton, Susan, Cowan, David, Broadwater, Gloria, Goldstein, Lori J., Martino, Silvana, Ingle, James N., Henderson, I. Craig, Norton, Larry, Winer, Eric P., Hudis, Clifford A., Ellis, Matthew J., and Berry, Donald A.
- Subjects
- *
PACLITAXEL , *EPIDERMAL growth factor , *CANCER in women , *BREAST cancer treatment , *HEALTH outcome assessment , *DOXORUBICIN , *DRUG therapy , *ADJUVANT treatment of cancer , *RANDOMIZED controlled trials , *CANCER treatment - Abstract
Background: The status of human epidermal growth factor receptor type 2 (HER2) in breast-cancer cells predicts clinical outcomes in women who receive adjuvant anthracycline-based chemotherapy. We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both. Methods: We randomly selected 1500 women from 3121 women with node-positive breast cancer who had been randomly assigned to receive doxorubicin (60, 75, or 90 mg per square meter of body-surface area) plus cyclophosphamide (600 mg per square meter) for four cycles, followed by four cycles of paclitaxel (175 mg per square meter) or observation. Tissue blocks from 1322 of these 1500 women were available. Immunohistochemical analyses of these tissue specimens for HER2 with the CB11 monoclonal antibody against HER2 or with a polyclonal-antibody assay kit and fluorescence in situ hybridization for HER2 amplification were performed. Results: No interaction was observed between HER2 positivity and doxorubicin doses above 60 mg per square meter. HER2 positivity was, however, associated with a significant benefit from paclitaxel. The interaction between HER2 positivity and the addition of paclitaxel to the treatment was associated with a hazard ratio for recurrence of 0.59 (P=0.01). Patients with a HER2-positive breast cancer benefited from paclitaxel, regardless of estrogen-receptor status, but paclitaxel did not benefit patients with HER2-negative, estrogen-receptor–positive cancers. Conclusions: The expression or amplification, or both, of HER2 by a breast cancer is associated with a benefit from the addition of paclitaxel after adjuvant treatment with doxorubicin (<60 mg per square meter) plus cyclophosphamide in node-positive breast cancer, regardless of estrogen-receptor status. Patients with HER2-negative, estrogen-receptor–positive, node-positive breast cancer may gain little benefit from the administration of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide. N Engl J Med 2007;357:1496-506. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
14. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer.
- Author
-
Hughes, Kevin S., Schnaper, Lauren A., Berry, Donald, Cirrincione, Constance, McCormick, Beryl, Shank, Brenda, Wheeler, Judith, Champion, Lorraine A., Smith, Thomas J., Smith, Barbara L., Shapiro, Charles, Muss, Hyman B., Winer, Eric, Hudis, Clifford, Wood, William, Sugarbaker, David, Henderson, I. Craig, and Norton, Larry
- Subjects
- *
LUMPECTOMY , *CANCER treatment , *BREAST cancer surgery , *CANCER in women , *TAMOXIFEN , *ESTROGEN antagonists , *WOMEN'S health - Abstract
Background: In women 70 years of age or older who have early breast cancer, it is unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus radiation therapy. Methods: Between July 1994 and February 1999, we randomly assigned 636 women who were 70 years of age or older and who had clinical stage I (T1N0M0 according to the tumor–node–metastasis classification), estrogen-receptor–positive breast carcinoma treated by lumpectomy to receive tamoxifen plus radiation therapy (317 women) or tamoxifen alone (319 women). Primary end points were the time to local or regional recurrence, the frequency of mastectomy for recurrence, breast-cancer–specific survival, the time to distant metastasis, and overall survival. Results: The only significant difference between the two groups was in the rate of local or regional recurrence at five years (1 percent in the group given tamoxifen plus irradiation and 4 percent in the group given tamoxifen alone, P<0.001). There were no significant differences between the two groups with regard to the rates of mastectomy for local recurrence, distant metastases, or five-year rates of overall survival (87 percent in the group given tamoxifen plus irradiation and 86 percent in the tamoxifen group, P=0.94). Assessment by physicians and patients of cosmetic results and adverse events uniformly rated tamoxifen plus irradiation inferior to tamoxifen alone. Conclusions: Lumpectomy plus adjuvant therapy with tamoxifen alone is a realistic choice for the treatment of women 70 years of age or older who have early, estrogen-receptor–positive breast cancer. N Engl J Med 2004;351:971-7. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.